HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer
ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
JB Pharma records revenue growth of 30% in Q1 FY23
Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad
Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
Lyka Labs swings back to profit in Q1FY23
Briefs: Zydus Lifesciences and Kimia Biosciences
Fortis Healthcare posts Q1 FY2023 consolidated PAT at Rs. 122.25 Cr
Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Subscribe To Our Newsletter & Stay Updated
Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants
Implementing a digital transformation in chemical operations to maximize profitability
The complexity of compliance
The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation
The guiding role of fluidized and spouted bed technologies in particle building processes
_100_100.jpg)
